F Star Therapeutics Inc Quick Ratio (FSTX) starting from the third quarter 2022 to third quarter 2021, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
F star Therapeutics Inc   (NASDAQ: FSTX)

F Star Therapeutics Inc 's Quick Ratio

FSTX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2022, Quick Ratio deteriorated to 2.57 below F Star Therapeutics Inc 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 380 other companies have achieved higher Quick Ratio than F Star Therapeutics Inc in third quarter 2022. While Quick Ratio total ranking in the third quarter 2022 has deteriorated compared to the prior quarter from 1024 to 1458.

Explain Quick Ratio?
How much Cash & cash equivalents FSTX´s has?
What are FSTX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

FSTX Quick Ratio (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2		 (Mar 31 2022)
Q1		 (Dec 31 2021)
Q4		 (Sep 30 2021)
Q3
Y / Y Current Liabilities Change 76.22 % 59.88 % -11.91 % -33.86 % 25.84 %
Y / Y Cash & cash equivalent Change -49.94 % -35.13 % 1769.59 % 323.99 % 255.59 %
Quick Ratio MRQ 2.57 3.66 5.85 7 9.04
FSTX's Total Ranking # 1458 # 1024 # 751 # 678 # 584
Seq. Current Liabilities Change -4.19 % 22.95 % 4.7 % 42.88 % -13.07 %
Seq. Cash & cash equivalent Change -32.84 % -23.02 % -12.41 % 10.55 % -12.98 %



Quick Ratio third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 381
Healthcare Sector # 673
Overall Market # 1458


Quick Ratio Statistics
High Average Low
15.91 7.44 0.28
(Jun 30 2017)   (Mar 31 2021)




Financial Statements
F Star Therapeutics Inc 's Current Liabilities $ 14 Millions Visit FSTX's Balance sheet
F Star Therapeutics Inc 's Cash & cash equivalent $ 36 Millions Visit FSTX's Balance sheet
Source of FSTX's Sales Visit FSTX's Sales by Geography


Cumulative F Star Therapeutics Inc 's Quick Ratio

FSTX's Quick Ratio for the trailling 12 Months

FSTX Quick Ratio

 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months		 (Dec 31 2021)
12 Months		 (Sep 30 2021)
12 Months
Y / Y Current Liabilities TTM Growth 8.61 % -0.68 % -4.35 % -21.37 % -6.41 %
Y / Y Cash & cash equivalent TTM Growth 34.86 % 119.13 % 356.64 % 114.48 % 43.77 %
Quick Ratio TTM 4.6 5.99 7.52 5.66 3.7
Total Ranking TTM # 4292 # 4224 # 629 # 528 # 4361
Seq. Current Liabilities TTM Growth 13.22 % 13.57 % -3.83 % -12.17 % 3.54 %
Seq. Cash & cash equivalent TTM Growth -13.08 % -9.56 % 27.72 % 34.32 % 41.24 %

Quick ratio ranking by company, industry and sector >> Back to FSTX Financial Strength Comparisons >> Go to Compare FSTX Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q3 2022 to $13.85 millions, cumulative Quick Ratio decreased to 4.6 below the F Star Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 577 other companies have achieved higher Quick Ratio than F Star Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2022 from 4224 to 4292.

Explain Quick Ratio?
How much Cash & cash equivalents FSTX´s has?
What are FSTX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 578
Healthcare Sector # 1146
Within the Market # 4292


trailing twelve months Quick Ratio Statistics
High Average Low
13.02 7.5 1.54
(Mar 31 2018)   (Mar 31 2021)




Companies with similar Quick Ratio in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2022 MRQ Cash & cash equivalentSep 30 2022 MRQ Current Liabilities
Assembly Biosciences Inc   7.03 $ 108.651  Millions$ 15.461  Millions
Rain Enhancement Technologies Holdco Inc   6.97 $ 90.708  Millions$ 13.013  Millions
Roivant Sciences Ltd   6.93 $ 1,599.021  Millions$ 230.744  Millions
Cypherpunk Technologies Inc   6.92 $ 78.308  Millions$ 11.318  Millions
Scynexis Inc   6.87 $ 96.090  Millions$ 13.995  Millions
Foghorn Therapeutics Inc   6.77 $ 373.498  Millions$ 55.210  Millions
Mustang Bio inc   6.74 $ 91.364  Millions$ 13.557  Millions
Crescent Biopharma Inc   6.67 $ 51.677  Millions$ 7.748  Millions
Vincerx Pharma Inc   6.63 $ 65.975  Millions$ 9.950  Millions
Gracell Biotechnologies Inc   6.61 $ 211.420  Millions$ 31.990  Millions
Phio Pharmaceuticals Corp  6.60 $ 14.484  Millions$ 2.194  Millions
Blue Water Vaccines Inc  6.58 $ 29.137  Millions$ 4.431  Millions
Zai Lab Limited  6.51 $ 1,119.476  Millions$ 171.880  Millions
Nektar Therapeutics  6.51 $ 546.387  Millions$ 83.989  Millions
Blueprint Medicines Corporation  6.48 $ 1,136.965  Millions$ 175.510  Millions
Syros Pharmaceuticals Inc   6.36 $ 244.481  Millions$ 38.424  Millions
Tff Pharmaceuticals Inc  6.33 $ 13.147  Millions$ 2.077  Millions
Immunic Inc   6.32 $ 72.771  Millions$ 11.514  Millions
Bio path Holdings inc   6.20 $ 13.650  Millions$ 2.201  Millions
Ngm Biopharmaceuticals Inc   6.18 $ 300.150  Millions$ 48.596  Millions
Cartesian Therapeutics Inc   6.17 $ 146.442  Millions$ 23.728  Millions
Apellis Pharmaceuticals Inc   6.14 $ 708.553  Millions$ 115.446  Millions
Nuvectis Pharma inc   6.14 $ 23.640  Millions$ 3.852  Millions
Merus N v   6.03 $ 387.022  Millions$ 64.150  Millions
Dogwood Therapeutics inc   5.99 $ 9.788  Millions$ 1.633  Millions
Repare Therapeutics Inc   5.99 $ 370.353  Millions$ 61.871  Millions
Zynerba Pharmaceuticals Inc   5.93 $ 55.934  Millions$ 9.431  Millions
Arcus Biosciences Inc   5.92 $ 1,048.782  Millions$ 177.176  Millions
Albireo Pharma inc   5.88 $ 222.476  Millions$ 37.819  Millions
Vistagen Therapeutics Inc   5.84 $ 35.287  Millions$ 6.045  Millions

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.